News
KZR
--
0.00%
--
Kala PDUFA, And Other News: The Good, Bad And Ugly Of Biopharma
Kala Pharmaceuticals on the go with upcoming PDUFA.Kezar announces Phase 2 KZR-616 trial update for polymyositis and dermatomyositis.Mirati Therapeutics announces positive clinical data for adagrasib.
Seekingalpha · 6h ago
Kezar Life Sciences' KZR-616 an Orphan Drug in U.S. for autoimmune inflammatory disorders
Kezar Life Sciences (KZR) is up 6% in premarket on Orphan Drug status by the FDA for KZR-616 for the treatment of polymyositis ((PM)) and dermatomyositis ((DM)).PM is a type of muscle
Seekingalpha · 5d ago
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)
Benzinga · 5d ago
Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
Benzinga · 5d ago
Kezar Life Sciences on Wednesday Received FDA Orphan Drug Designation for their Treatment for Polymyositis on October 21
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=663518
Benzinga · 6d ago
We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 10/19 19:25
Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced six presentations during four upcoming medical and scientific conferences.
Business Wire · 10/15 11:00
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
INO, BKR, KODK and AHT among after-hours movers
Gainers: [[JAX]] +14%. [[KZR]] +10.3%. [[AHT]] +8%. [[KODK]] +7.9%. [[OM]] +5%.Losers: [[INO]] -3.8%. [[BTU]] -3.7%. [[EPRT]] -3.2%. [[BKR]] -3%. [[MYO]] -2.8%.
Seekingalpha · 09/17 21:44
Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted data from the Phase 1b portion of the MISSION study demonstrating safety, tolerability and early efficacy signals
Business Wire · 09/17 21:01
Encouraging lupus data lifts Kezar Life Sciences, up 9% after hours
Kezar Life Sciences (KZR) is up 9% after hours in reaction to data from the Phase 1b portion of the Phase 1/2 MISSION study evaluating lead candidate KZR-616 in patients with systemic
Seekingalpha · 09/17 20:52
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
Kezar Life Sciences (KZR) Investor Presentation - Slideshow
The following slide deck was published by Kezar Life Sciences, Inc. in conjunction with this event.
Seekingalpha · 09/11 21:46
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings:Citius Pharmaceuticals (CTXR): $100M.Flexion Therapeutics (FLXN): $300M.SCYNEXIS (SCYX): $200M.Kezar Life Sciences (KZR): $200M.
Seekingalpha · 09/11 20:41
Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced company presentations and participation at upcoming patient and medical conferences.
Business Wire · 09/10 12:00
Kezar Life Sciences: Exploring New Options For Autoimmune Diseases
KZR-616 is a new promising first-in-class selective proteasome inhibitor, which might help patients with autoimmune diseases, such as lupus, polymyositis, and dermatomyositis.The share price recently surged due to recent results of the Phase 1b/2 trial MISSION.Kezar successfully raised additional capital for further development, making it an interesting candidate on our watchlist.
Seekingalpha · 09/07 13:54
Kezar Life Sciences, Inc. (KZR) CEO John Fowler on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 09:32
Kezar Life Sciences EPS beats by $0.04
Kezar Life Sciences (NASDAQ:KZR): Q2 GAAP EPS of -$0.22 beats by $0.04. Cash, cash equivalents and marketable securities totaled $157.5 M Press Release
seekingalpha · 08/06 01:08
Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2020 financial results and corporate highlights.
Business Wire · 08/05 20:01
Kezar Life Sciences to Participate in Two Upcoming Virtual Investor Conferences
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upco
Business Wire · 08/03 20:01
Webull provides a variety of real-time KZR stock news. You can receive the latest news about Kezar Life Sciences through multiple platforms. This information may help you make smarter investment decisions.
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.
More